Skip to main content
SpringerLink
Log in

Rituximab maintenance in indolent lymphoma: Indications and controversies

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Over the past few years it has been shown in previously untreated and relapsed/refractory follicular lymphoma that rituximab maintenance has a clear clinical benefit after induction with rituximab plus chemotherapy, chemotherapy alone, or rituximab monotherapy. However, the optimal dose, schedule, and duration of rituximab maintenance therapy still need to be established. The important issue of maintenance treatment versus retreatment upon relapse is the topic of the ongoing large randomized phase III Rituximab Extended Schedule or Retreatment Trial (RESORT). Current data indicate that rituximab maintenance can be safely administered for up to 2 years, although assessment of long-term safety requires longer follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Johnson PW, Rohatiner AZ, Whelan JS, et al.: Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995, 13:140–147.

    PubMed  CAS  Google Scholar 

  2. Yuen AR, Kamel OW, Halpern J, Horning S: Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995, 13:1726–1733.

    PubMed  CAS  Google Scholar 

  3. Ezdinli EZ, Harrington DP, Kucuk O, et al.: The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin’s lymphoma. Cancer 1987, 60:156–160.

    Article  PubMed  CAS  Google Scholar 

  4. Steward WP, Crowther D, McWilliam LJ, et al.: Maintenance chlorambucil after CVP in the management of advanced-stage, low-grade histologic type non-Hodgkin’s lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 1988, 61:441–447.

    Article  PubMed  CAS  Google Scholar 

  5. Aviles A, Duque G, Talavera A, Guzman R: Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 1996, 20:495–499.

    PubMed  CAS  Google Scholar 

  6. Arranz R, Garcia-Alfonso P, Sobrino P, et al.: Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin’s lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998, 16:1538–1546.

    PubMed  CAS  Google Scholar 

  7. Fisher RI, Dana BW, LeBlanc M, et al.: Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin’s lymphoma: results of the Southwest Oncology Group randomized Phase III study 8809. J Clin Oncol 2000, 18:2010–2016.

    PubMed  CAS  Google Scholar 

  8. Hagenbeek A, Carde P, Meerwaldt JH,, et al.: Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin’s lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998, 16:41–47.

    PubMed  CAS  Google Scholar 

  9. Rohatiner A, Radford J, Deakin D, et al.: A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001, 85:29–35.

    Article  PubMed  CAS  Google Scholar 

  10. Rohatiner AZ, Gregory WM, Peterson B, et al.: Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005, 23:2215–2223.

    Article  PubMed  CAS  Google Scholar 

  11. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833.

    PubMed  CAS  Google Scholar 

  12. Schmitz K, Brugger W, Weiss B, et al.: Clonal selection of CD20-negative non-Hodgkin’s lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol 1999, 106:571–572.

    Article  PubMed  CAS  Google Scholar 

  13. Davis TA, Czerwinski DK, Levy R: Therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin Cancer Res 1999, 5:611–615.

    PubMed  CAS  Google Scholar 

  14. Hainsworth JD, Litchy S, Burris HA III, et al.: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 2002, 20:4261–4267.

    Article  PubMed  CAS  Google Scholar 

  15. Hainsworth JD, Litchy S, Morrissey L, et al.: Rituximab as first-line and maintenance therapy for indolent non-Hodgkin’s lymphoma (NHL): long-term follow-up of a Minnie Pearl Cancer Research Network Phase II trial [abstract]. Blood 2003, 102:411a–412a.

    Google Scholar 

  16. Ghielmini M, Schmitz S-FH, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma a significantly increases event-free survival and response duration compared with the standard weekly x4 schedule. Blood 2004, 103:4416–4423.

    Article  PubMed  CAS  Google Scholar 

  17. Hochster HS, Weller E, Ryan T, et al.: Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) [abstract]. J Clin Oncol 2004, 22(Suppl):6502.

    Google Scholar 

  18. Hochster HS, Weller E, Gascoyne RD, et al.: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B [abstract]. Blood 2005, 106:106a.

    Google Scholar 

  19. van Oers MHJ, Klasa R, Marcus RE, et al.: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin’s lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 2006, 108:3295–3301.

    Article  PubMed  Google Scholar 

  20. Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide and mitoxantrone (FCM) significantly prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphoma: results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 2004, 104:3064–3071.

    Article  PubMed  CAS  Google Scholar 

  21. Dreyling MH, Forstpointner R, Ludwig W, et al.: Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. J Clin Oncol 2005, 23(Suppl):6528.

    Google Scholar 

  22. Forstpointner R, Unterhalt M, Dreyling M, et al.: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas-results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003–4008.

    Article  PubMed  CAS  Google Scholar 

  23. Dreyling MH, Forstpointner R, Boeck H, et al.: Combined immuno-chemotherapy followed by rituximab maintenance is an effective salvage treatment after prior rituximab containing therapy: results of a GLSG-subgroup analysis in patients with relapsed indolent lymphoma [abstract]. Blood 2006, 108:2769.

    Google Scholar 

  24. Hainsworth JD, Litchy S, Shaffer DW, et al.: Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005, 23:1088–1095.

    Article  PubMed  CAS  Google Scholar 

  25. Hainsworth JD, Meng C, Spigel DR, et al.: Long-term follow-up of patients with follicular lymphoma (FL) treated with two years of maintenance rituximab: response to rituximab retreatment at progression [abstract]. Blood 2006, 108:4723.

    Google Scholar 

  26. Berinstein NL, Grillo-Lopez AJ, et al.: Association of serum rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998, 9:995–1001.

    Article  PubMed  CAS  Google Scholar 

  27. Gordan LN, Grow WB, Pusateri A, et al.: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005, 23:1096–1102.

    Article  PubMed  CAS  Google Scholar 

  28. Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005, 31:456–473.

    Article  PubMed  CAS  Google Scholar 

  29. Ghielmini M, Schmitz SF, Burki K, et al.: The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000, 11(Suppl 1):123–126.

    Article  PubMed  Google Scholar 

  30. Fogarty GB, Bayne M, Bedford P, et al.: Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab. Clin Oncol (R Coll Radiol) 2006, 18:155–156.

    CAS  Google Scholar 

  31. Herold M, Pasold R, Srock S, et al.: Rituximab plus mitoxantrone, chlorambucil, prednisolone (R-MCP) is superior to MCP alone in advanced indolent and follicular lymphoma — results of a Phase III study (OSHO39) [abstract]. Ann Oncol 2005, 16(Suppl 5):v51–v52.

    Google Scholar 

  32. Hiddemann W, Kneba M, Dreyling M, et al.: Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced-stage follicular lymphomas as compared to CHOP alone, results of a prospective randomised study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2005, 106:3725–3732.

    Article  PubMed  CAS  Google Scholar 

  33. Marcus R, Imrie K, Belch A, et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417–1423.

    Article  PubMed  CAS  Google Scholar 

  34. Salles G, Foussard C, Mounier N, et al.: Rituximab added to alfa IFN-CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients [abstract]. Blood 2004, 104:49a–50a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Marinus H.J. van Oers MD, PhD

Authors
  1. Marinus H.J. van Oers MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marinus H.J. van Oers MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Oers, M.H. Rituximab maintenance in indolent lymphoma: Indications and controversies. Curr Oncol Rep 9, 378–383 (2007). https://doi.org/10.1007/s11912-007-0051-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-007-0051-y

Search

Navigation